Company news
Sareum Holdings Plc (LSE:SAR) news
Sareum Holdings Plc news releases on 6ix. Latest, Jul 20, 2026: Completion of Dosing in Toxicology Programme
Press releases & updates
Completion of Dosing in Toxicology Programme
July 20, 2026
Publication of Phase 1 data on SDC-1801 in BJCP
June 22, 2026
Half-Year Report for Six Months Ended 31 Dec 2025
March 12, 2026
Restart of Phase 2-enabling toxicology programme
February 17, 2026
Results of AGM
December 9, 2025
Annual General Meeting Statement
December 9, 2025
Notice of AGM, Annual Report and Accounts
November 17, 2025
Appointment of Joint Corporate Broker
October 30, 2025
Preliminary Results for Year Ended 30 June 2025
October 23, 2025
Update on toxicology study for SDC-1801
October 10, 2025
Notice of Results and Investor Presentation
October 7, 2025
Exercise of Warrants
September 26, 2025
Sareum Collaboration with Receptor.AI
August 12, 2025
Appointment of Sole Broker
July 4, 2025
Initiation of Toxicology Studies for SDC-1801
May 29, 2025
Update on TYK2/JAK1 and SRA737 Programmes
April 28, 2025
Director’s Dealing
March 27, 2025
Sareum : Half-yearly Results to Dec 2024
March 26, 2025
Sareum Half-Year Report
March 25, 2025
Notice of HY Results and Investor Presentation
March 20, 2025
Institutional Equity Fundraise
March 13, 2025
Sareum Acquires Licence for SRA737
March 13, 2025
Update on SRA737
December 31, 2024
AGM Statement
December 19, 2024
Appointment of Joint Broker
December 18, 2024
Holding(s) in Company
December 17, 2024
Award of Share Options
December 16, 2024
Sareum : Notice of AGM 2024
November 26, 2024
Sareum : Annual Report 2023/24
November 26, 2024
Final Results for the Year Ended 30 June 2024
October 29, 2024
Notice of Final Results and Investor Presentation
October 23, 2024
Further Subscription to raise £1,000,000
October 21, 2024
Subscription to raise £2,364,000
October 11, 2024
Patent Allowance in China
September 16, 2024
US patent allowance
September 2, 2024
Management Changes
July 10, 2024
Positive Data from SDC-1801 Phase 1 Clinical Trial
July 1, 2024
Sareum : Half-yearly Results to Dec 2023
April 29, 2024
Final Issue of RiverFort Subscription Shares
April 23, 2024
Issue of RiverFort Subscription Shares
April 19, 2024
Completion of Equity Fundraise
April 4, 2024
Result of WRAP Retail Offer
April 2, 2024
Increase in size of WRAP Retail Offer
April 2, 2024
WRAP Retail Offer
March 28, 2024
Equity Fundraise
March 28, 2024
New Patent Allowance
March 15, 2024
Notice of Interim Results and Trading Update
March 12, 2024
Update on SDC-1801 Clinical Trial Progress
February 15, 2024
Development and commercialisation licence SRA737
January 2, 2024
Drawdown of Equity Prepayment Facility
November 23, 2023